Myelodysplastic Syndromes (MDS)

Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…

Abstract Background We aimed to study outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients aged above 70 with using post-transplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD)…

Abstract Purpose of Review In inherited bone marrow failure syndromes (IBMFS), clonal hematopoiesis (CH) has been increasingly recognized as a molecular fingerprint of the underlying pathophysiology. A specific clonal profile has been reported in telomere biology disorders (TBDs)…

Key Points Timely manufacture of VCAR33, a donor-derived CD33-directed CAR T, was feasible in patients with relapsed/refractory AML after alloHCT. VCAR33 had an acceptable safety profile at doses up to 3 × 106 cells/kg and demonstrated antileukemic activity with a response rate…

Correspondence The Myelodysplastic/Myeloproliferative neoplasm (MDS/MPN) overlap syndromes are a heterogeneous group of rare hematologic malignancies characterized by features of both MDS such as morphologic dysplasia and cytopenias and MPNs including elevated blood counts and…

Key Points: Many patients and caregivers associate early palliative care (EPC) with hospice or death, a misperception that may persist even after gaining a better understanding of the role of EPC and may prevent them from experiencing the benefits of EPC. Cultural or religious…

Abstract Allogeneic hematopoietic cell transplantation (ASCT) is the only curative option for patients with myelodysplastic syndromes (MDS), but whether cytoreductive pretreatment and molecular “downstaging” according to the IPSS-M improves outcomes remains unclear. We…

ABSTRACT Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective treatment for patients with high-risk hematologic malignancies. Over the last decade, gut microbiota composition during allo-HCT has been associated with patients' outcomes. Treatment-related…

In this issue of Blood, Muffly et al1 demonstrate in a phase 1 trial the feasibility and safety of CD117-targeted, precision preconditioning for allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) and myelodysplastic neoplasia (MDS). Almost 70…